Literature DB >> 16152608

Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population.

Zhibin Hu1, Hongxia Ma, Daru Lu, Ji Qian, Jiannong Zhou, Yijiang Chen, Lin Xu, Xinru Wang, Qingyi Wei, Hongbing Shen.   

Abstract

Overexpression of MDM2 may attenuate the P53 stress response pathway through direct blocking of P53 transcriptional activity and mediating P53 degradation. Two promoter polymorphisms (one is a T to G substitution at the intronic P53-response promoter, and the other is a 40-bp insertion/deletion polymorphism in the constitutive promoter) were identified, and recently the T/G substitution (SNP309) has been demonstrated to alter the levels of MDM2 gene products. In this molecular epidemiological study with 717 incident lung cancer cases and 1,083 cancer-free controls, we genotyped these 2 promoter polymorphisms of MDM2 and evaluated their associations with risk of lung cancer. We found that there were no significant associations between MDM2 SNP309 variant genotypes and lung cancer risk (adjusted OR = 1.20, 95% CI = 0.95-1.53 for TG and adjusted OR = 1.12, 95% CI = 0.85-1.48 for GG, respectively). Similarly, we did not find evidence for any association between risk of lung cancer and MDM2 insertion/deletion polymorphism. The findings suggest that these two MDM2 promoter polymorphisms may not play a major role in lung cancer susceptibility in this Chinese population. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16152608     DOI: 10.1002/ijc.21463

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

2.  Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population.

Authors:  Wen Li; Shuang Shuang Wang; Jing Deng; Jian Xin Tang
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

3.  Lack of an Association between a Functional Polymorphism in the MDM2 Promoter and Breast Cancer in Women in Northeast Iran.

Authors:  Zeinab Tavakkol Afshari; Amin Reza Nikpoor; Jalil Tavakkol Afshari; Rashin Ganjali; Parvaneh Sanglakh Ghoochan Atigh; Fatemeh Homaei Shandiz; Khadijeh Jamialahmadi
Journal:  Rep Biochem Mol Biol       Date:  2017-10

4.  Involvement of single-nucleotide polymorphisms in predisposition to head and neck cancer in Saudi Arabia.

Authors:  Khaled S Al-Hadyan; Najla M Al-Harbi; Sara S Al-Qahtani; Ghazi A Alsbeih
Journal:  Genet Test Mol Biomarkers       Date:  2011-08-30

5.  Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.

Authors:  Datong Zheng; Yanping Chen; Caijie Gao; Yongyue Wei; Guochun Cao; Nan Lu; Yayi Hou; Xiuqin Jiang; Jianjun Wang
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

6.  Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.

Authors:  Hui Wan Chua; Daniel Ng; Serena Choo; San San Lum; Huihua Li; Li Ying Soh; Kanaga Sabapathy; Adeline Seow
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

7.  Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population.

Authors:  Jyh-Der Leu; I-Feng Lin; Ying-Fang Sun; Su-Mei Chen; Chih-Chao Liu; Yi-Jang Lee
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 8.  Genetic susceptibility to lung cancer--light at the end of the tunnel?

Authors:  Ariela L Marshall; David C Christiani
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

9.  Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk.

Authors:  Yasuaki Enokida; Kimihiro Shimizu; Seiichi Kakegawa; Jun Atsumi; Yoshiaki Takase; Yohei Miyamae; Toshiteru Nagashima; Yoichi Ohtaki; Kyoichi Kaira; Noriaki Sunaga; Noriko Yanagitani; Reiko Yoshino; Katsuhiko Tsunekawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Kengo Usui; Alexander Lezhava; Yoshio Tomizawa; Toshihisa Ishikawa; Masami Murakami; Yoshihide Hayashizaki; Izumi Takeyoshi
Journal:  Biomed Rep       Date:  2014-06-26

10.  No association of MDM2 SNP309 with risk of glioblastoma and prognosis.

Authors:  Soufiane El Hallani; Yannick Marie; Ahmed Idbaih; Mathieu Rodero; Blandine Boisselier; Florence Laigle-Donadey; François Ducray; Jean-Yves Delattre; Marc Sanson
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.